BioInvent
First patient dosed in Transgene and BioInvent’s phase 1 trial
October 10, 2023Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial
Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
June 2, 2023Research and Development BioInvent, NSCLC, Oncology, monoclonal antibody
Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal …
BioInvent and Transgene announce positive phase 1a solid tumour trial data
May 25, 2023Research and Development BioInvent, Oncology, Transgene, clinical trials, oncology, tumours
Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from a trial studying BT-001 for …
BioInvent receives $3m payment for antibodies selected by Pfizer
December 23, 2020Research and Development BioInvent, Cancer, Pfizer
BioInvent International, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, …
Blow for BioInvent as vascular treatment fails
July 11, 2012Research and Development, Sales and Marketing BI-204, BioInvent, LDL, Sweden
Swedish biotech company BioInvent has suffered a new blow with the failure of its lead pipeline candidate. The company’s share …
Encouraging data for ThromboGenics and BioInvent product
May 7, 2010BioInvent, Lovenox, ThromboGenics, VTE
An antibody-based drug to prevent blood clots after orthopaedic surgery has shown promising results in phase II. TB-402 is a …
Latest content
Five Facts about cardiovascular disease
